NEW YORK (GenomeWeb) - Singulex said today that it has secured a Phase II Fast Track Small Business Innovation Research contract from the National Cancer Institute to develop biomarker assays to determine the effectiveness of potential cancer therapeutics.
 
The agreement extends a contract with NCI that Singulex originally signed in November 2007.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new study finds that a placental protein linked with preeclampsia can be targeted by RNA silencing, according to the New Scientist.

A settlement is expected in a Duke University lawsuit hinging on using falsified data to win grants, Retraction Watch and Science report.

In PNAS this week: approach for analyzing the expression of endogenous retroviruses, circular RNAs that influence host-virus interactions, and more.

A phylogenetic analysis finds that the rare hemimastigotes form their own supra-kingdom, CBC reports.